Additional file 5: Figure S4. of MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1

  • Priscila Daniele Ramos Cirilo (Creator)
  • Luciana Nogueira de Sousa Andrade (Contributor)
  • Bruna R. Correa (Creator)
  • Mei Qiao (Creator)
  • Tatiane Katsue Furuya (Contributor)
  • Roger Chammas (Creator)
  • Luiz O Penalva (Contributor)



MicroRNA-195 and drugs in SK-MEL-5 melanoma cells. (a-b) Cell viability rate was calculated based on the proliferation index ratio (%) of treated cells/not treated cells (control). Increasing doses of cisplatin (2.5, 5.0, and 10.0 μM) and temozolomide (50, 250, and 450 μM) were tested. (c-d) FlowJo Cytometry Analysis software was used for hypodiploid cell quantification after propidium iodide staining. Cells were treated with 2.5 and 5.0 μM cisplatin and 50 and 250 μM temozolomide drugs. (e-f) Apoptosis index based on caspase 3/7 activity was measured in a luminometer. All results showed that alone miR-195 exerts a effect in SK-MEL-5 melanoma cells compared to cisplatin and temozolomide treatments. All experimental data were obtained 24 h after miRNA-control/miR-195 (10 nM) transfection plus 48 h of drug exposure (total time 72 h). Statistical analysis were carried out using ANOVA with multiple comparison test and are reported as means ± SD. Representative data of at least three independent experiments are reported. NS: non-significant; *P ≤ 0.05; **** P ≤ 0.0001. (PNG 514 kb)
Date made available2017

Cite this